Business
AstraZeneca to run fresh COVID-19 vaccine trial amid results confusion – The Australian Financial Review
AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.
AstraZeneca and its partner, the University of Oxford, reported on Monday that a lower initial dose of the vaccine, followed by a full dose, produced a 90 per cent efficacy rate, compared with 62 per cent for two full doses.
A day after the data were unveiled the head of the US vaccine program known as Operation Warp Speed said that the regimen showing the higher level of effectiveness was tested in a younger population. He also said that the half-dose was given to some people because of an error…
-
Business22 hours ago3 of the best ASX stocks to buy now with $2,500
-
General16 hours agoActivism under the guise of good intentions
-
Noosa News16 hours agoHow errors, penalties and bad decisions helped New South Wales beat themselves in Origin II
-
Noosa News22 hours agoBrisbane’s 2025–26 budget revealed: rate hikes, service fee rises and major infrastructure plans